July 2026 · HeydayMD Research
Access gaps, at-home testing adoption, and why men's digital health is 5-10 years behind women's
Quick answer: The State of Men's Hormone Health 2026 report highlights significant access gaps, rising at-home testing adoption, and a lag in men's digital health investment compared to women's health. A large percentage of adult men experience low testosterone while remaining undiagnosed, often due to friction in traditional testing processes. At-home blood collection devices and telehealth integration are shifting how men access hormone screening, with treatment decisions ultimately determined by a licensed clinician following lab work.
Start here: testosterone therapy at HeydayMD · could it be low testosterone? · at-home testing
Testosterone deficiency affects an estimated 10-40% of adult men globally, yet the vast majority remain undiagnosed. Unlike cholesterol or blood pressure — tests that are routine parts of annual physicals — testosterone panels are rarely included in standard primary care screenings.
Traditional testosterone testing requires:
This multi-step process creates friction at every stage — particularly for working men who can't easily take time off for morning lab appointments.
At-home blood collection technology has matured significantly. Upper-arm devices use microsampling to collect clinically valid blood samples from the upper arm — no venipuncture, no fasting facility visit, no time off work.
The shift to at-home collection isn't just about convenience — it's fundamentally changing who gets tested. Men who would never schedule a LabCorp appointment are now testing their hormone levels because the barrier dropped from "take a morning off work" to "5 minutes at your kitchen table."
Women's digital health has attracted over $3B in venture funding since 2020. Companies like Maven Clinic ($300M+ raised), Kindbody ($195M), and Tia ($132M) have built comprehensive platforms for women's reproductive and hormonal health.
Men's hormone health? The landscape is fragmented:
In 2025, the U.S. Department of Defense began implementing routine testosterone screening for active-duty service members. The rationale: low testosterone affects readiness, recovery, and cognitive performance.
If the military considers testosterone important enough to screen routinely, why don't civilian primary care providers?
"The military's decision to screen for testosterone isn't about bodybuilding — it's about recognizing that hormone health is foundational to physical and mental performance. Civilian medicine should take note."
This report synthesizes published clinical research, market data, and platform observations from HeydayMD's patient base. Key sources include: Endocrine Society clinical practice guidelines, Grand View Research testosterone market reports, Cleveland Clinic men's health survey data, and publicly available venture funding data. Patient-level statistics are based on anonymized, aggregate HeydayMD platform data.
HeydayMD ships at-home lab kits to your door. No lab visit, no time off work. Results in 48 hours, then a virtual visit with a licensed provider.
Take the Free Assessment →